{Reference Type}: Journal Article
{Title}: Preliminary evidence in treatment of eosinophilic gastroenteritis in children: A case series.
{Author}: Chen Y;Sun M;Chen Y;Sun M;
{Journal}: World J Clin Cases
{Volume}: 10
{Issue}: 19
{Year}: Jul 2022 6
{Factor}: 1.534
{DOI}: 10.12998/wjcc.v10.i19.6417
{Abstract}: <B>BACKGROUND: </B>Eosinophilic gastroenteritis is a rare inflammatory disorder in children. However, there is still no standard guideline in the treatment of pediatric eosinophilic gastroenteritis.<BR><B>OBJECTIVE: </B>To report our experience with the diagnosis and treatment of children with eosinophilic gastroenteritis.<BR><B>METHODS: </B>From January 2017 to December 2019, a total of 22 children were diagnosed with eosinophilic gastroenteritis.<BR><B>RESULTS: </B>Endoscopic examination showed eosinophil infiltration in the duodenum [mean number of eosinophils/high-power field (HPF) = 53.1 ± 81.5], stomach (mean number of eosinophils/HPF = 36.8 ± 50.5), and terminal ileum (mean number of eosinophils/HPF = 49.0 ± 24.0). All 18 children with low eosinophil infiltration (< 14%) responded well to the initial drug treatment without relapse, while two of four children with high eosinophil infiltration (> 14%) relapsed after initial methylprednisolone/montelukast treatment. In addition, children with high eosinophil infiltration (> 14%) showed symptomatic relief and histological remission without further relapse after receiving budesonide/methylprednisolone as initial or relapse treatment.<BR><B>CONCLUSIONS: </B>Methylprednisolone/montelukast is still the best treatment for children with low eosinophil infiltration (< 14%). Budesonide can be considered as the initial or relapse treatment for children with high eosinophil infiltration (> 14%).